BioSpace News Archive

Flagship Pioneering, the bioplatform innovation company, announced the launch of Metaphore Biotechnologies, a company harnessing the power of biomimicry and machine learning to unlock the transformative therapeutic potential of functional molecular mimics.

Cambrex announced that Snapdragon Chemistry has completed the second phase of its 51,000 square foot expansion in Waltham, Massachusetts.

IDEAYA Biosciences, Inc. announced that it has amended its clinical trial collaboration and supply agreements with Pfizer Inc. to support evaluation of darovasertib and crizotinib combination therapy in the company’s planned Phase 2/3 registrational clinical trial in MUM and to continue support of the company’s ongoing Phase 2 clinical trial in MUM.

Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, presented data for its CD45 Shielded Cell & Immunotherapy Pair program at the American Society of Gene and Cell Therapy’s Annual Meeting in Los Angeles.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that it will release first quarter 2023 results and corporate update on Tuesday, May 23, 2023.

Caris Life Sciences® announced that Robert H. Lurie Comprehensive Cancer Center of Northwestern University has joined the Caris Precision Oncology Alliance™.

NanoViricides, Inc., reports that it has filed its Quarterly Report on Form 10-Q for the fiscal third quarter ending March 31, 2023 with the Securities and Exchange Commission on Monday, May 15, 2023.

Coherus BioSciences, Inc. announced the pricing of its underwritten public offering of 11,764,706 shares of its common stock at a price to the public of $4.25 per share.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the first quarter of 2023 and provided a business update.

BD (Becton, Dickinson and Company) today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the new BD Kiestra™ Methicillin-resistant Staphylococcus aureus (MRSA) imaging application that uses artificial intelligence (AI) to interpret bacterial growth and release negative specimens with minimal human interaction.